# Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

> **NCT05174806** · PHASE2 · COMPLETED · sponsor: **Microbion Corporation** · enrollment: 47 (actual)

## Conditions studied

- Diabetic Foot Infection
- Diabetic Foot

## Interventions

- **DRUG:** Topical Pravibismane
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT05174806
- **Lead sponsor:** Microbion Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2024-01-19
- **Final completion:** 2024-01-19
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174806, "Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05174806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*